Opko Health Inc. (NASDAQ:OPK) shows potential with a recent collaboration agreement with Regeneron Pharmaceuticals Inc. through its subsidiary ModeX Therapeutics. The deal includes an upfront payment of $7 million and potential milestone payments exceeding $200 million per selected molecule.